Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

INSANE: Lexaria - The Real Truth

Why Are Lexaria Bioscience Shares Soaring 45% After Hours?

Lexaria Bioscience Corp. (NASDAQ: LEXX) experienced a dramatic 45.10% surge in after-hours trading on Thursday, climbing to $2.22 from its closing price of $1.53. According to Benzinga Pro data, the biotech company’s regular trading session had already shown strength with a 7.75% gain.

Benzinga · Sep 26, 2025

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) announced positive topline results from KarMMa-3, a Phase 3 study evaluating Abecma (idecabtagene vicleucel) compared to standard combination regimens in adults with multiple myeloma that is relapsed and refractory. Bristol Myers shares traded in a range of $73.95 to $75.32 on a day volume…

Benzinga · Aug 10, 2022

LEXX: Put Your Drinks Up! Four Deals Signed in June

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT

Benzinga · Aug 8, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193 in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58…

Benzinga · Jul 27, 2022

Lexaria's DehydraTECH CBD Hypertension Study Dosing Complete With No Serious Adverse Events

Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) revealed that dosing with Lexaria's DehydraTECH-processed CBD has been completed in its multi-week human clinical hypertension study HYPER-H21-4

Benzinga · Jul 27, 2022

Why Shares Of Lexaria Biosciences Are Trading Higher

Lexaria Bioscience Corp. (NASDAQ: LEXX) shares are trading higher after the company announced manufacturing and license agreements with BevNology.

Benzinga · Jun 21, 2022

Lexaria Posied To Receive US Patent For DehydraTECH To Deliver Antiviral Drugs

Lexaria Bioscience Corp (NASDAQ:LEXX) is receiving its first-ever patent for DehydraTECH technology in the enhanced delivery of antiviral drugs. Lexaria has received notification from the United States Patent and Trademark Office that patent 11,311,559 for Compositions and Methods For Enhanced Delivery Of Antiviral Agents will be issued to the Company on April 26. "This…

Benzinga · Apr 21, 2022

Read news from The Economist, FT, and more,
with one subscription

Why Lexaria Shares Are Rising Today

Lexaria Bioscience Corp (NASDAQ:LEXX) said that all data analyses from its simulated pulmonary hypertension clinical study HYPER-H21-3 are complete, assessing a single 300mg dose of DehydraTECH-processed cannabidiol (DehydraTECH-CBD). The study findings indicated a tendency (p=0.1) during 15 minutes of simulated low levels of oxygen (hypoxia) for reduced pulmonary artery systolic pressure (PASP)…

Benzinga · Apr 14, 2022

Coverage From

Benzinga

People

John Vandermosten

46 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

European Medicines Agency

77 stories

Amgen Inc

76 stories

US Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.